<DOC>
	<DOCNO>NCT00040170</DOCNO>
	<brief_summary>This study involve use experimental product , TG4010 . The purpose study determine TG4010 stimulate body 's immune system help fight cancer .</brief_summary>
	<brief_title>Vaccine Study MVA-MUC1-IL2 Patients With Prostate Cancer</brief_title>
	<detailed_description>The experimental product , TG4010 , modify vaccinia virus ( already use human ) two ( 2 ) gene place . One gene protein ( MUC1 ) find cancer cell . The second gene human interleukin 2 ( IL2 ) body 's immune system make help fight cancer . The TG4010 give injection skin ( subcutaneous ) week six week follow schedule every three week every three week first twelve ( 12 ) week . If therapy working , continue 9 month improvement patient get bad long tolerate .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Rising PSA surgery radiation prostate cancer Metastasis local disease Prior hormone treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Adenocarcinoma prostate</keyword>
</DOC>